Zeltiq Aesthetics CFO Patrick F. Williams Sells 1,000 Shares (ZLTQ)
Zeltiq Aesthetics (NASDAQ:ZLTQ) CFO Patrick F. Williams sold 1,000 shares of the company’s stock on the open market in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $17.17, for a total transaction of $17,170.00. Following the transaction, the chief financial officer now directly owns 92,795 shares in the company, valued at approximately $1,593,290. The transaction was disclosed in a filing with the SEC, which is available at this link.
Shares of Zeltiq Aesthetics (NASDAQ:ZLTQ) traded down 0.75% during mid-day trading on Thursday, hitting $15.88. 202,123 shares of the company’s stock traded hands. Zeltiq Aesthetics has a 52-week low of $5.01 and a 52-week high of $24.79. The stock has a 50-day moving average of $17.14 and a 200-day moving average of $18.41. The company’s market cap is $593.9 million.
Zeltiq Aesthetics (NASDAQ:ZLTQ) last released its earnings data on Tuesday, April 29th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.05. The company had revenue of $31.00 million for the quarter, compared to the consensus estimate of $27.54 million. Analysts expect that Zeltiq Aesthetics will post $-0.39 EPS for the current fiscal year.
A number of research firms have recently commented on ZLTQ. Analysts at Cantor Fitzgerald reiterated a “positive” rating on shares of Zeltiq Aesthetics in a research note on Monday, May 5th. Separately, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Zeltiq Aesthetics in a research note on Wednesday, April 30th. They now have a $20.00 price target on the stock. Finally, analysts at Canaccord Genuity cut their price target on shares of Zeltiq Aesthetics from $26.00 to $24.00 in a research note on Wednesday, April 30th. They now have a “buy” rating on the stock. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $23.40.
Zeltiq Aesthetics, Inc operates as a medical device development company. It engages in the design, development, and commercialization of non-invasive procedures for the reduction of unwanted fat tissue.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.